1. A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford–AstraZeneca COVID‐19 vaccine. (7th June 2022) Authors: Filippi, F.; Baraldi, C.; Zinzani, P.L.; Casadei, B.; Pileri, A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 10(2022) Page Start: e747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA. (12th June 2019) Authors: Wang, M.; Belada, D.; Cheah, C.; Chu, M.P.; Dreyling, M.; Flinn, I.; Fogliatto, L.; Goy, A.; Inwards, D.; Jurczak, W.; Mayer, J.; Re, F.; Robak, T.; Spurgeon, S.; Yoon, S.S.; Zinzani, P.L.; Yin, M.; Chen, T.; Kahl, B. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 554 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. (August 2016) Authors: Zinzani, P.L.; Sasse, S.; Radford, J.; Gautam, A.; Bonthapally, V. Journal: Critical reviews in oncology/hematology Issue: Volume 104(2016) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. (August 2016) Authors: Zinzani, P.L.; Sasse, S.; Radford, J.; Gautam, A.; Bonthapally, V. Journal: Critical reviews in oncology/hematology Issue: Volume 104(2016) Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017) Authors: Kim, Y.H.; Prince, H.M.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca‐Wessels, M.C.; Wood, K.W.; Li, M.; Liu, Y.; Lin, H.; Little, M.; Danaee, H.; Trepicchio, W.; Dummer, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CONCORDANCE BETWEEN IMMUNOHISTOCHEMISTRY AND GENE EXPRESSION PROFILING SUBTYPING FOR DIFFUSE LARGE B‐CELL LYMPHOMA IN THE PHASE 3 PHOENIX TRIAL. (12th June 2019) Authors: Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L.H.; Johnson, P.; Zinzani, P.L.; Carey, J.; Liu, G.; Loefgren, C.; Shreeve, M.; Sun, S.; Zhuang, S.; Vermeulen, J.; Staudt, L.M.; Younes, A.; Wilson, W. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Panayiotidis, P.; Kellner, A.; Follows, G.A.; Mollica, L.; Nagler, A.; Özcan, M.; Santoro, A.; Hiemeyer, F.; Liu, L.; Garcia‐Vargas, J.; Childs, B.H.; Zinzani, P.L.; Dreyling, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 399 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. EFFICACY AND SAFETY IN HIGH‐RISK RELAPSED OR REFRACTORY INDOLENT FOLLICULAR LYMPHOMA PATIENTS TREATED WITH COPANLISIB. (12th June 2019) Authors: Dreyling, M.; Santoro, A.; Leppä, S.; Demeter, J.; Follows, G.A.; Lenz, G.; Kim, W.S.; Mollica, L.; Nagler, A.; Phipps Diong, C.; Provencio, M.; Magagnoli, M.; Munoz, J.; Hiemeyer, F.; Liu, L.; Miriyala, A.; Rodrigues, L.; Garcia‐Vargas, J.; Childs, B.H.; Zinzani, P.L. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. (20th August 2021) Authors: Cowan, R.A.; Scarisbrick, J.J.; Zinzani, P.L.; Nicolay, J.P.; Sokol, L.; Pinter‐Brown, L.; Quaglino, P.; Iversen, L.; Dummer, R.; Musiek, A.; Foss, F.; Ito, T.; Rosen, J‐P.; Medley, M.C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 11(2021) Page Start: 2225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides (MF): results from the MAVORIC study. (2019) Authors: Scarisbrick, J.; Geskin, L.J.; Bagot, M.; Fisher, D.C.; Elmets, C.; Duvic, M.; Beylot-Barry, M.; Kim, E.J.; Moriya, J.; Leoni, M.; Zinzani, P.L. Journal: European journal of cancer Issue: Volume 119(2019)Supplement 1 Page Start: S31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗